Underestimated effect of antiphospholipid antibodies on arteriovenous fistula maturation in hemodialysis patients
Abstract Background: Arteriovenous fistula delay or absence of maturation is a common problem in hemodialysis. The prevalence of antiphospholipid antibody is higher among hemodialysis patients compared to the general population and is inconsistently associated with arteriovenous fistula thrombosis or stenosis. However, the effect of antiphospholipid antibodies on delayed or absence of maturation of the arteriovenous fistula has never been studied. Methods: We retrospectively identified 103 hemodialyzed patients with arteriovenous fistula whether used or not. We collected the clinical and biological data potentially involved in arteriovenous fistula maturation and investigated the association between antiphospholipid antibody positivity and arteriovenous fistula maturation failure according to KDOQI guidelines. Results: In our cohort, the prevalence of arteriovenous fistula maturation failure was of 45.8%. The prevalence of antiphospholipid syndrome was of 7.8 %, whereas only 10.7% of patients fulfilled only antiphospholipid laboratory criteria. The persistent positivity of antiphospholipid antibody was a risk factor for arteriovenous fistula maturation failure. In multivariate analysis, this association was independent of stenosis. Conclusions: To our knowledge, we report for the first time, a statistically significant association between arteriovenous fistula maturation failure, antiphospholipid antibody persistent positivity and antiphospholipid syndrome. This association was independent of arteriovenous stenosis. Our data suggests a potential non-stenotic and/or non-thrombotic mechanism of antiphospholipid antibody related arteriovenous fistula maturation failure in hemodialysis patients..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 17. Juni Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Taghavi, Maxime [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-1606215/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA035960531 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA035960531 | ||
| 003 | DE-627 | ||
| 005 | 20230429192758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220511s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-1606215/v1 |2 doi | |
| 035 | |a (DE-627)XRA035960531 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-1606215/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Taghavi, Maxime |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Underestimated effect of antiphospholipid antibodies on arteriovenous fistula maturation in hemodialysis patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: Arteriovenous fistula delay or absence of maturation is a common problem in hemodialysis. The prevalence of antiphospholipid antibody is higher among hemodialysis patients compared to the general population and is inconsistently associated with arteriovenous fistula thrombosis or stenosis. However, the effect of antiphospholipid antibodies on delayed or absence of maturation of the arteriovenous fistula has never been studied. Methods: We retrospectively identified 103 hemodialyzed patients with arteriovenous fistula whether used or not. We collected the clinical and biological data potentially involved in arteriovenous fistula maturation and investigated the association between antiphospholipid antibody positivity and arteriovenous fistula maturation failure according to KDOQI guidelines. Results: In our cohort, the prevalence of arteriovenous fistula maturation failure was of 45.8%. The prevalence of antiphospholipid syndrome was of 7.8 %, whereas only 10.7% of patients fulfilled only antiphospholipid laboratory criteria. The persistent positivity of antiphospholipid antibody was a risk factor for arteriovenous fistula maturation failure. In multivariate analysis, this association was independent of stenosis. Conclusions: To our knowledge, we report for the first time, a statistically significant association between arteriovenous fistula maturation failure, antiphospholipid antibody persistent positivity and antiphospholipid syndrome. This association was independent of arteriovenous stenosis. Our data suggests a potential non-stenotic and/or non-thrombotic mechanism of antiphospholipid antibody related arteriovenous fistula maturation failure in hemodialysis patients. | ||
| 700 | 1 | |a Demulder, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Mesquita, Maria Do Carmo Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a Dernier, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Nortier, Joëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Collart, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Pozdzik, Agnieszka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 17. Juni |
| 773 | 1 | 8 | |g year:2022 |g day:17 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-1606215/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 17 |c 06 | ||
| 953 | |2 045F |a 570 | ||